Administration of Tat-CHIP dose-dependently ameliorated ischemia-induced hyperlocomotion 1 day after ischemia induction and improved neuronal survival in the CA1 region 4 days after ischemia induction based on immunohistochemical staining for NeuN. This evidence concerns the gene RBFOX3 and ischemia.